Gilead Sciences (GILD) has announced that its remdesivir drug has received emergency FDA approval for the treatment of severe cases of Covid-19.“It is reasonable to believe that the known and potential benefits of RDV outweigh the known and potential risks of the drug for the treatment of patients hospitalized with severe COVID-19” the FDA wrote in its approval letter to Gilead.The decision was based on review of the topline data from the randomized, double-blinded, placebo-controlled trial conducted by The National Institute of Allergy and Infectious Diseases (NIAID) and from the Gilead-sponsored open-label trial that evaluated different durations of remdesivir.Following the …read more
Source:: Yahoo Finance
